Sensorion reports new positive clinical results presented at the World Congress of Audiology

Regulatory news:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore, treat and prevent hearing loss, today announced detailed results from its clinical programs (SENS-501 and SENS-401), which were presented on September 20, 2024 during a company-hosted symposium and oral presentation at the 36th World Congress of Audiology in Paris, France.

Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Sensorion is making tremendous progress in its hearing aid franchise with innovative therapies to restore, prevent and treat hearing loss conditions. In particular, we have made significant progress in our Audigen clinical gene therapy trial to restore hearing in very young patients born with severe to profound hearing loss caused by mutations in the gene encoding otoferlin. This program received regulatory approval in January 2024 and we are confident today that we will have treated the first group of patients by the end of 2024, with one patient already injected and two more patients already screened. I am very grateful to the parents of these patients for their trust and to the study researchers involved in this study for their commitment.